5 Pharmaceutical Stocks to Buy Now According to Billionaire Kerr Neilson

Page 5 of 5

1. Gilead Sciences, Inc. (NASDAQ:GILD)

Stake Value of Platinum Asset Management: $81,347,000

Percentage of Platinum Asset Management’s 13F Portfolio: 2.26%

Number of Hedge Fund Holders: 54

Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company that develops drugs in the areas of unmet medical need including HIV, hepatitis B, hepatitis C, and influenza in the United States, Europe, and internationally. This February, the company reported earnings per share of $0.69 for the fiscal fourth quarter of 2021 and generated quarterly revenues of $7.24 billion, beating revenue estimates by $0.60 million.

On April 12, Piper Sandler analyst Do Kim raised his price target on Gilead Sciences, Inc. (NASDAQ:GILD) to $72 from $71 and maintained a Neutral rating on the shares.

Gilead Sciences, Inc. (NASDAQ:GILD) is a popular stock pick among value investors. By the end of the fourth quarter of 2021, Gilead Sciences, Inc. (NASDAQ:GILD) was spotted on 54 hedge fund portfolios. The total stakes of these funds came to $2.36 billion, up from $1.75 billion in the prior quarter with 55 positions. The hedge fund sentiment for the stock is positive.

ClearBridge Investments recently published its fourth-quarter 2021 investor letter in which it mentioned Gilead Sciences, Inc. (NASDAQ:GILD). Here is what the firm had to say about the stock:

“Other pharma companies are providing solutions as well. Biopharmaceutical company Gilead Sciences’ remdesivir, sold under the brand name Veklury, is a broad-spectrum antiviral medication administered by intravenous infusion; it can shorten the time to recovery in hospitalized patients and reduce the risk of hospitalization and death in non-hospitalized patients.”

You can also take a look at 10 Best Pharmaceutical Stocks to Buy According to Cathie Wood and 10 Best Pharmaceutical Stocks to Buy According to Billionaire Joseph Edelman.

Page 5 of 5